Guilin Sanjin Of China Seeks To Be First To Try IPO In Nine Months
This article was originally published in PharmAsia News
Executive Summary
China's Guilin Sanjin Pharmaceutical is busy promoting itself to potential institutional investors as it attempts to be the nation's first company to go public in nine months. Guilin Sanjin is launching an initial public offering, now free to do so after regulators lifted a freeze on IPOs as of June 18. The medium-size drug maker seeks to raise nearly $93 million by going public. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.